Venetoclax维奈妥拉,1257044-40-8

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Venetoclax

CAS No. : 1257044-40-8

MCE 国际站：Venetoclax

产品活性：Venetoclax (ABT-199; GDC-0199) 是一种高效，有选择性和口服有效的 Bcl-2 抑制剂，K_i 小于0.01 nM。Venetoclax 可以诱导自噬 (autophagy) 作用。

研究领域：Apoptosis  |  Autophagy

作用靶点：Bcl-2 Family  |  Autophagy

In Vitro: Venetoclax (ABT-199) potently kills FL5.12-BCL-2 cells (EC₅₀=4 nM), Venetoclax (ABT-199) shows much weaker activity against FL5.12-BCL-XL cells (EC₅₀=261 nM). ABT-199 also shows selectivity in cellular mammalian two-hybrid assays, where it disrupts BCL-2-BIM complexes (EC₅₀=3 nM) but is much less effective against BCL-XL-BCL-XS (EC₅₀=2.2 μM) or MCL-1-NOXA complexes.

In Vivo: After a single oral dose of 12.5 mg per kg body weight in xenografts derived from RS4;11 cells (ALL), Venetoclax (ABT-199) causes a maximal tumor growth inhibition (TGI_max) of 47% (P<0.001) and tumor growth delay (TGD) of 26% (P<0.05).
Treatment of established xenografted (a mouse xenograft model of the T-ALL cell line LOUCY) tumors with Venetoclax (ABT-199) 100 mg/kg for 4 days results in a significant reduction of leukemic burden.

相关产品：Covalent Screening Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Peptidomimetic Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Anti-diabetic Compound Library  |  Anti-COVID-19 Compound Library  |  Orally Active Compound Library  |  Chemical Probe Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Targeted Therapy Drug Library   |  Mitochondria-Targeted Compound Library  |  Targeted Diversity Library  |  Rare Diseases Drug Library  |  Protein-protein Interaction Inhibitor Library  |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Heterocyclic Compound Library  |  Off-patent Drug Library  |  Mitochondrial Toxicity Compound Library  |  Highly Selective Inhibitors Library  |  Highly Selective Activators Library  |  Cell Death Library  |  Navitoclax  |  Polyinosinic-polycytidylic acid  |  S63845  |  ABT-737  |  A-1331852  |  AZD-5991  |  BT2  |  Chlorin e6  |  A-1155463  |  MIK665  |  Estradiol benzoate  |  BAI1  |  Benzbromarone  |  Obatoclax Mesylate  |  Digitoxin  |  Chelerythrine chloride  |  BI-3802  |  AZD4320  |  Dehydrocorydaline  |  WEHI-539 hydrochloride  |  Tapotoclax  |  Amantadine  |  A-1210477  |  Gambogic Acid  |  BTSA1  |  Bax inhibitor peptide V5  |  UMI-77  |  Cardamonin  |  TCPOBOP  |  Daphnetin

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds